Search is Powered by Google
Pharma Industry / Biotech Industry News

Biogenerics Would Reduce Health Care Costs For Patients, Says GPhA

Main Category: Pharma Industry / Biotech Industry
Also Included In: Public Health
Article Date: 25 Jul 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The Generic Pharmaceutical Association (GPhA) today said the availability of a workable pathway that provides timely patient access to safe, affordable and life-saving biogeneric medicines would save consumers and the health care system billions of dollars. The skyrocketing prices of certain prescription drugs were the focus of a Joint Economic Committee hearing on Capitol Hill yesterday (www.jec.senate.gov).

"Countless patients in need of life-saving biopharmaceutical treatments are struggling to afford their high costs. For patients facing serious conditions such as cancer and heart disease, safe and affordable biogenerics would allow them to improve their lives while reducing their health care costs," said GPhA President and CEO Kathleen Jaeger. "With some biopharmaceuticals costing hundreds of thousands of dollars per year, patients must have timely access to life-saving biogeneric medicines."

According to several studies, the availability of biogenerics would save the health care system billions of dollars each year. A study by Insmed, a biotech company, estimated $67 billion to $108 billion in savings over 10 years, with $236 billion to $378 billion in savings over 20 years for generic versions of the top 12 categories of biologics with patents that either have expired or are soon to expire. A study conducted on behalf of the Pharmaceutical Care Manufacturers Association (PCMA) estimated $14.9 billion in savings over a standard 10-year scoring period for certain biopharmaceuticals in the top 200 Medicare Part B reimbursed categories. And Express Scripts estimated $71 billion in savings over 10 years for products in four therapeutic categories -- interferons, erythropoietin, growth hormone, and insulin.

"These are significant savings that we cannot afford to ignore. That's why the Food and Drug Administration needs a workable approval pathway for biogenerics -- one without lengthy and overreaching market exclusivity provisions or patent extensions that simply result in an empty promise to patients," said Jaeger.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 65% of the total prescriptions dispensed in the United States, but only 20% of all dollars spent on prescription drugs.

http://www.gphaonline.org

Ad Banner - Patient Recruitment and Retention in Clinical Trials 28-29th October 2008, Philadelphia, PA


Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


What to Look For When You Want to Get Rid of the Ink
What to Look For When You Want to Get Rid of the Ink

Experts say you should go to a board-certified dermatologist, who is experienced with lasers and specializes in removing tattoos. It's also good to know what can and can't be removed.

more videos are available in our health videos section.